Blog
RSS FeedPosted by Michael Wonder on 17 Sep 2021
Keytruda made available on the NHS for certain oesophageal cancer patients
17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...
Posted by Michael Wonder on 16 Sep 2021
BioCryst’s HAE med Orladeyo wins NICE nod
16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...
Posted by Michael Wonder on 15 Sep 2021
NICE backs Opdivo for head and neck cancer
15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...
Posted by Michael Wonder on 13 Sep 2021
UK terminates Valneva COVID-19 vaccine supply agreement
13 September 2021 - The UK government has terminated its supply agreement with French firm Valneva for its COVID-19 vaccine ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 11 Sep 2021
MHRA statement on booster doses of Pfizer and AstraZeneca COVID-19 vaccines
9 September 2021 - The regulatory changes made by the MHRA today give further options for the deployment programme. ...
Posted by Michael Wonder on 10 Sep 2021
MHRA approves Amgen’s Lumykras under Project Orbis
10 September 2021 - Amgen has announced that is first-in-class KRAS G12C inhibitor Lumykras (sotorasib) has been received a conditional ...
Posted by Michael Wonder on 10 Sep 2021
UK approval for Pfizer’s JAK inhibitor Cibinqo
10 September 2021 - The UK MHRA has approved a marketing authorisation for Pfizer’s oral Janus kinase 1 inhibitor Cibinqo ...
Posted by Michael Wonder on 09 Sep 2021
NICE recommends treatment for people with juvenile idiopathic arthritis
9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...
Posted by Michael Wonder on 09 Sep 2021
Albireo receives UK MHRA approval of Bylvay (odevixibat)
8 September 2021 - Bylvay now approved in U.S., EU and UK as first drug treatment for patients with progressive familial intrahepatic ...
Posted by Michael Wonder on 08 Sep 2021
Nivolumab scores a rare 'no' from NICE
8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...
Posted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 06 Sep 2021
UK MHRA grants GenSight Biologics’ Lumevoq ophthalmic gene therapy Promising Innovative Medicine Designation
6 September 2021 - GenSight Biologics today announced that its gene therapy Lumevoq has been granted Promising Innovative Medicine designation by ...
Posted by Michael Wonder on 04 Sep 2021
GSK’s shingles vaccine Shingrix gains UK license
2 September 2021 - GlaxoSmithKline's Shingrix has been licensed in the UK for the prevention of shingles in adults aged ...
Posted by Michael Wonder on 04 Sep 2021
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...